Clinical Trials Logo

Blindness clinical trials

View clinical trials related to Blindness.

Filter by:

NCT ID: NCT06064565 Recruiting - Clinical trials for Leber Congenital Amaurosis

Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial (LIGHT)

Start date: January 10, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutations in RPE65 gene.

NCT ID: NCT06027216 Recruiting - Blind Right Eye Clinical Trials

Multiplexing Prism Fitting for Field Expansion of Monocular Vision

Start date: December 27, 2023
Phase: N/A
Study type: Interventional

The investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye). The investigators are testing a simplified design and fitting protocol to provide field expansion for individuals with acquired monocular vision.

NCT ID: NCT06024668 Not yet recruiting - Blind Right Eye Clinical Trials

Simulated Walking With Multiplexing Prism for Field Expansion in Monocular Vision

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye). The investigators will test the efficacy of the prism in improving the detection of colliding pedestrians during a simulated walking task.

NCT ID: NCT06024057 Not yet recruiting - Clinical trials for To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)

An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

To evaluate the scaling clinical trail of AAV2-RPE65 gene therapy agent (LX101) in patients with congenital amaurosis (LCA).

NCT ID: NCT06023927 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

Obstructive Sleep Apnea as a Risk Factor for Normal Tension Glaucoma and a Crucial Step in Preventing Blindness

Start date: April 15, 2024
Phase:
Study type: Observational

The purpose of this research study is to learn more about the relationship between Obstructive Sleep Apnea (OSA) and Normal Tension Glaucoma (NTG). OSA is a nighttime disorder of the upper airway that causes an intermittent lack of oxygen while sleeping. NTG is a type of glaucoma that occurs despite the normal intraocular pressure levels, making its detection more difficult. Left untreated, irreversible optic nerve damage and extensive vision loss can result. Previous research has shown some evidence between OSA and the development of NTG. The investigators are researching whether undergoing treatment for OSA would help to improve the vascular health to the retina, and in effect, improve the early signs of visual dysfunction seen with diagnostic testing.

NCT ID: NCT05992415 Not yet recruiting - Cataract Clinical Trials

New York City Eye Study (NYCES)

NYCES
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

Dr. Lisa A. Hark (PI and Study Chair) and an interdisciplinary team have designed the New York City Eye Study (NYCES) to promote eye and vision health equity and address eye health disparities in adults age 21+ (PAR-23-009/NOT-EY-22-004).

NCT ID: NCT05956730 Active, not recruiting - Clinical trials for Low Vision Blindness

Audio-guided Home Physical Activity to Support People With Low Vision: Physical Performance and Quality of Life

Start date: November 4, 2020
Phase: N/A
Study type: Interventional

The aim of the project is to investigate the effectiveness of a home training managed through audio-guides in comparison to a classic supervised training on the physical and psychological parameters of patients with severe low vision. In this study the feasibility and effectiveness of a self-managed physical activity protocol with audio guides on physical performance (strength, mobility and aerobic capacity) will be assessed and compared to the same protocol supervised in a fitness environment. Secondary aims are the effects of the two types of administration of the protocol on quality of life, autonomy and psychological impact on the caregiver.

NCT ID: NCT05906953 Recruiting - Clinical trials for Leber Congenital Amaurosis

Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)

Start date: October 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutations in RPE65 gene.

NCT ID: NCT05894434 Not yet recruiting - Clinical trials for Hemianopia, Homonymous

Ameliorating Stroke-induced Hemianopia Via Multisensory Training

Start date: August 2024
Phase: N/A
Study type: Interventional

This study seeks to determine the extent of the visual capabilities that can be restored in hemianopic stroke patients by a multisensory training technique and evaluate changes in the brain that the training induces. The effectiveness of the technique will be evaluated in two interventional contexts: patients whose blindness is long-standing and stable, and another in which intervention is as soon as possible after the stroke.

NCT ID: NCT05806684 Not yet recruiting - Premature Clinical Trials

Hyperbilirubinemia and Retinopathy of Prematurity in Preterm Infants: a Retrospective Study.

biliROP
Start date: May 1, 2023
Phase:
Study type: Observational

The goal of this retrospective observational study is to [learn about the correlation between hyperbilirubinemia and retinopathy of prematurity in preterm infants. The main question it aims to answer are: • To evaluate the possible effect of neonatal jaundice linked to the presumed protective antioxidant action of bilirubin on the development of ROP, compared to a control group which, although presenting ROP, did not develop jaundice.